4.7 Article

Docking and stability defects in mitofusin highlight the proteasome as a potential therapeutic target

Journal

ISCIENCE
Volume 26, Issue 7, Pages -

Publisher

CELL PRESS
DOI: 10.1016/j.isci.2023.107014

Keywords

-

Ask authors/readers for more resources

Defects in mitochondrial fusion play a role in many diseases. Mitofusins use self-interaction and GTP hydrolysis to drive membrane remodeling events. The mechanisms by which mitofusins mediate outer membrane fusion are still not fully understood, but structural studies provide insights and possible therapeutic interventions for mitofusin-associated diseases.
Defects in mitochondrial fusion are at the base of many diseases. Mitofusins power membrane-remodeling events via self-interaction and GTP hydrolysis. However, how exactly mitofusins mediate fusion of the outer membrane is still unclear. Structural studies enable tailored design of mitofusin variants, providing valuable tools to dissect this stepwise process. Here, we found that the two cysteines conserved between yeast and mammals are required for mitochondrial fusion, revealing two novel steps of the fusion cycle. C381 is dominantly required for the formation of the trans-tethering complex, before GTP hydrolysis. C805 allows stabilizing the Fzo1 protein and the trans-tethering complex, just prior to membrane fusion. Moreover, proteasomal inhibition rescued Fzo1 C805S levels and membrane fusion, suggesting a possible application for clinically approved drugs. Together, our study provides insights into how assembly or stability defects in mitofusins might cause mitofusin-associated diseases and uncovers potential therapeutic intervention by proteasomal inhibition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available